Literature DB >> 7955583

A continuing assessment of risk factors for the development of Escherichia coli O157:H7-associated hemolytic uremic syndrome.

N Cimolai1, S Basalyga, D G Mah, B J Morrison, J E Carter.   

Abstract

Univariate and multivariate analyses were applied to determine risk factors for the progression of Escherichia coli O157:H7 enteritis to hemolytic uremic syndrome (HUS). Both clinical and laboratory variables were assessed for 118 pediatric patients (28 HUS; 90 enteritis only). Verotoxins 1 and 2 were produced by 89% of E. coli strains whereas verotoxin 2 only was produced by 11%. Although a greater frequency of strains producing verotoxin 2 only occurred in HUS isolates (p = 0.11), toxin phenotype was not significantly associated with risk after multivariate analyses. HUS patients with or without neurological manifestations had similar frequencies of the two toxin phenotypes among their isolates. Significant associations for young age (RR = 0.984; 95% CI = 0.971-0.998) and prolonged use of antidiarrheal agents (RR = 44.11; 95% CI = 8.48-229.4) with HUS were apparent. A lesser chance of progression was observed for patients whose strains possessed a 4 kb plasmid (RR = 0.27; 95% CI = 0.08-0.94). Our results are consistent with the hypothesis that progression to HUS is dependent upon both bacterial virulence factors and the clinical characteristics of the individual patient.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7955583

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  19 in total

1.  Escherichia coli infections and hemolytic-uremic syndrome.

Authors:  N Cimolai
Journal:  CMAJ       Date:  2001-05-15       Impact factor: 8.262

Review 2.  Shiga Toxin-Producing Escherichia coli Infection, Antibiotics, and Risk of Developing Hemolytic Uremic Syndrome: A Meta-analysis.

Authors:  Stephen B Freedman; Jianling Xie; Madisen S Neufeld; William L Hamilton; Lisa Hartling; Phillip I Tarr; Alberto Nettel-Aguirre; Anderson Chuck; Bonita Lee; David Johnson; Gillian Currie; James Talbot; Jason Jiang; Jim Dickinson; Jim Kellner; Judy MacDonald; Larry Svenson; Linda Chui; Marie Louie; Martin Lavoie; Mohamed Eltorki; Otto Vanderkooi; Raymond Tellier; Samina Ali; Steven Drews; Tim Graham; Xiao-Li Pang
Journal:  Clin Infect Dis       Date:  2016-02-24       Impact factor: 9.079

Review 3.  Chronic sequelae of E. coli O157: systematic review and meta-analysis of the proportion of E. coli O157 cases that develop chronic sequelae.

Authors:  Jessica Keithlin; Jan Sargeant; M Kate Thomas; Aamir Fazil
Journal:  Foodborne Pathog Dis       Date:  2013-11-27       Impact factor: 3.171

Review 4.  Shiga toxin-producing Escherichia coli O104:H4: an emerging pathogen with enhanced virulence.

Authors:  Dakshina M Jandhyala; Vijay Vanguri; Erik J Boll; Yushuan Lai; Beth A McCormick; John M Leong
Journal:  Infect Dis Clin North Am       Date:  2013-07-24       Impact factor: 5.982

Review 5.  Guidelines for the management and investigation of hemolytic uremic syndrome.

Authors:  Takashi Igarashi; Shuichi Ito; Mayumi Sako; Akihiko Saitoh; Hiroshi Hataya; Masashi Mizuguchi; Tsuneo Morishima; Kenji Ohnishi; Naohisa Kawamura; Hirotsugu Kitayama; Akira Ashida; Shinya Kaname; Hiromichi Taneichi; Julian Tang; Makoto Ohnishi
Journal:  Clin Exp Nephrol       Date:  2014-08       Impact factor: 2.801

6.  The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections.

Authors:  C S Wong; S Jelacic; R L Habeeb; S L Watkins; P I Tarr
Journal:  N Engl J Med       Date:  2000-06-29       Impact factor: 91.245

Review 7.  Diarrheagenic Escherichia coli.

Authors:  J P Nataro; J B Kaper
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

8.  Frequency and distribution of diarrhoeagenic Escherichia coli strains isolated from pediatric patients with diarrhoea in Bosnia and Herzegovina.

Authors:  Amela Dedeić-Ljubović; Mirsada Hukić; Daria Bekić; Amra Zvizdić
Journal:  Bosn J Basic Med Sci       Date:  2009-05       Impact factor: 3.363

9.  [Treatment of typical hemolytic-uremic syndrome. Knowledge gained from analyses of the 2011 E. coli outbreak].

Authors:  J Menne; J T Kielstein; U Wenzel; R A K Stahl
Journal:  Internist (Berl)       Date:  2012-12       Impact factor: 0.743

Review 10.  All blood, no stool: enterohemorrhagic Escherichia coli O157:H7 infection.

Authors:  Jang W Yoon; Carolyn J Hovde
Journal:  J Vet Sci       Date:  2008-09       Impact factor: 1.672

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.